Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 USD | +2.74% | +7.66% | -44.52% |
May. 01 | Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration | MT |
May. 01 | Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration | CI |
Evolution of the average Target Price on Editas Medicine, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Editas Medicine, Inc.
Barclays | |
RBC Capital Markets | |
Truist Securities | |
Citigroup | |
JPMorgan Chase | |
Stifel Nicolaus | |
Chardan Research | |
Raymond James | |
Credit Suisse | |
Cantor Fitzgerald | |
Morgan Stanley | |
SVB Securities LLC | |
Wells Fargo Securities | |
BofA Securities | |
Baird | |
Oppenheimer | |
Goldman Sachs | |
SVB Leerink | |
Evercore ISI | |
Chardan | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- EDIT Stock
- Consensus Editas Medicine, Inc.